The University of Arizona College of Medicine-Phoenix will receive $5.5 million over five years from the Flinn Foundation to support translational research in cardiovascular diseases, neurosciences, and serious mental illnesses.Continue reading
Category Archives: AZBio News
BIO Statement on CMS National Coverage Determination for Drugs Used to Treat Patients Suffering from Alzheimer’s Disease
On April 7, 2022, the Centers for Medicare & Medicaid Services (CMS) released a national policy for coverage of aducanumab (brand name Aduhelm™) and any future monoclonal antibodies directed against amyloid approved by the FDA with an indication for use in treating Alzheimer’s disease. In its official statement, the Biotechnology Innovation Organization (BIO) shares why the CMS Decision is an enormous setback for Alzheimer’s patients and a dangerous infringement on FDA’s Scientific Autonomy.
HTG Expands Features of Proprietary HTG EdgeSeq Technology
New Sample Preparation Harmonization Designed to Enable miRNA and mRNA Profiling Without the Need for Additional Sample
Study describes new method for probing the bewildering diversity of the microbiom
In recent years, researchers have begun to explore the vast assemblage of microbes on and within the human body. These include protists, archaea, fungi, viruses and vast numbers of bacteria living in symbiotic ecosystems.
Aqualung Therapeutic’s ALT-100 Monoclonal Antibody Cited as A Novel Therapeutic for Lung Fibrosis
TUCSON, AZ / ACCESSWIRE / April 4, 2022 / Aqualung Therapeutics, an early-stage immunotherapeutics biotech company developing an anti-inflammatory therapeutic platform for unchecked inflammation has published another study touting the effectiveness of its anti-inflammatory ALT-100 monoclonal antibody (mAb)
Phoenix to be Site of New UArizona Health Sciences Center Targeting Immunotherapies
The Center for Advanced Molecular and Immunological Therapies will provide staff, facilities, support and services to advance precision medicine.
Castle Biosciences to Acquire AltheaDx
Furthers mid- and long-term growth with strategic advance into pharmacogenomics and mental healthContinue reading
Booth Udall Fuller Offer Intellectual Property Office Hours for AZBio Members
In partnership with Arizona BioIndustry Association (AZBio), Booth Udall are offering weekly office hours to give AZBio members the opportunity to ask questions about the protection of their intellectual property assets and general considerations for their IP strategy.
Valley Fever Collaborative – Creating Defenses Against Disease
The Valley Fever Collaborative is an initiative that supports a collaborative effort between Arizona’s three state universities focused on the development of precision medicine approaches, drug development and environmental risk abatement to reduce the financial cost and human burden of Valley Fever.
Get Engaged In the SBIR STTR Reauthorization Discussion
The SBIR/STTR Programs are currently set to expire on September 30, 2022. It would be damaging to American innovation and competitiveness if these programs were to expire before a full reauthorization can be passed. The SBIR/STTR Programs enable small businesses to develop and commercialize new innovative technologies and have a proven track record of promoting competition through a merit-based application process. Since their establishment in 1982, these programs have provided over 179,000 awards, totaling more than $54.3 billion, to U.S. small businesses. A study by the National Academy of Sciences found a commercialization rate of 50-60% for SBIR/STTR investments. You can see the impact of SBIR/STTR in Arizona by clicking here.